I-Acute Lymphoblastic Leukemia(T-ALL)-09

Umfundi waseyunivesithi ogama linguMengmeng waseYanjiao, eGuizhou, wafumana unyango olusebenzayo kwisibhedlele saseLudaopei.

UMengmeng, obhinqileyo, oneminyaka engama-21 ubudala, thaca kwikliniki yethu yezigulana ezingalaliswayo nge-22 kaJuni ngo-2021, ngokudinwa okuzingileyo. Uvavanyo lwesiqhelo lwegazi lubonise i-WBC 479×10^9/L. Uvavanyo olongezelelweyo lomongo lwaqinisekisa i-acute lymphoblastic leukemia (T-cell subtype). Uye wafumana imijikelo emibini yechemotherapy, kodwa i-leukemia yahlala ingaphenduli, kunye ne-MRD (isifo esincinci esishiyekileyo) kwi-56.01%, kwaye wayenokubandakanyeka kwinkqubo ye-nervous central leukemia.

Ngomhla we-13 ka-Agasti, i-lymphocyte ye-autologous yaqokelelwa kwaye i-chemotherapy yalawulwa. Nge-30 ka-Agasti, uMengmeng wafumana i-CD7 CAR-T cell infusion. Kwiiveki ezimbini emva kokuxilwa, uvavanyo lomongo wethambo lubonise uxolelo olupheleleyo, ukungakhathali kwe-MRD, kunye nokulawulwa kwenkqubo ye-nervous central leukemia. Ufumene i-grade 1 ye-cytokine release syndrome (CRS) impendulo ngaphandle kwenkqubo ye-nervous ye-central reactions ezimbi.